Mycenax Biotech (4726) — Financial Flexibility Index
Mycenax Biotech (4726) has a Financial Flexibility Index of -0.02x as of September 2025. Free cash flow of NT$-25.73 Million (operating CF NT$-50.35 Million minus capex NT$24.62 Million) represents 0% of total liabilities (NT$1.69 Billion). Check 4726 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Mycenax Biotech Financial Flexibility Index (2017–2024)
Historical Financial Flexibility Index trend for Mycenax Biotech across 8 annual periods. For the full cash flow conversion analysis, see 4726 cash generation efficiency.
Annual Financial Flexibility Index for Mycenax Biotech (2017–2024)
Year-by-year free cash flow to debt coverage for Mycenax Biotech. Explore how well can Mycenax Biotech service its debt to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (TWD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.10x | NT$138.83 Million | NT$-191.68 Million | NT$1.34 Billion | ▼ -17.9% |
| 2023 | 0.13x | NT$166.42 Million | NT$-131.18 Million | NT$1.32 Billion | ▼ -64.5% |
| 2022 | 0.35x | NT$476.75 Million | NT$-150.19 Million | NT$1.35 Billion | ▼ -54.2% |
| 2021 | 0.77x | NT$951.86 Million | NT$-146.23 Million | NT$1.23 Billion | ▼ -3.8% |
| 2020 | 0.80x | NT$434.39 Million | NT$174.17 Million | NT$540.89 Million | ▲ +561.3% |
| 2019 | 0.12x | NT$37.17 Million | NT$-140.74 Million | NT$306.04 Million | ▲ +141.6% |
| 2018 | -0.29x | NT$-61.79 Million | NT$-180.27 Million | NT$211.70 Million | ▼ -207.3% |
| 2017 | 0.27x | NT$45.96 Million | NT$-45.55 Million | NT$168.93 Million | — |